Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315) Announces January 2026 Share Capital and Public Float Update

Bulletin Express

Feb 03

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. presented a monthly return of equity movements for the period ended January 31, 2026. The total authorized share capital remained at RMB 446,898,420, comprising RMB 110,781,920 in H shares and RMB 336,116,500 in A shares.

According to the announcement, there were no changes to the number of issued shares for either the H-share or A-share classes during the reporting period. The H-share count stood at 110,781,920, while the A-share count remained 336,116,500. No treasury shares or other share movements were reported.

In addition, the public float requirement for the listed H shares was met as of the end of January 2026, with no disclosures regarding any non-compliance. The company did not report any details on share options, warrants, convertibles, or other share issuance arrangements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1181959686"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181959686\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181959686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181959686","market":"us","top_or_hot":-1,"title":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315) Announces January 2026 Share Capital and Public Float Update","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. presented a monthly return of equity movements for the period ended January 31, 2026. The total authorized share capital remained at RMB 446,898,420, comprising RMB 110,781,920 in H shares and RMB 336,116,500 in A shares.</p>\n<p>According to the announcement, there were no changes to the number of issued shares for either the H-share or A-share classes during the reporting period. The H-share count stood at 110,781,920, while the A-share count remained 336,116,500. No treasury shares or other share movements were reported.</p>\n<p>In addition, the public float requirement for the listed H shares was met as of the end of January 2026, with no disclosures regarding any non-compliance. The company did not report any details on share options, warrants, convertibles, or other share issuance arrangements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315) Announces January 2026 Share Capital and Public Float Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315) Announces January 2026 Share Capital and Public Float Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-03 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. presented a monthly return of equity movements for the period ended January 31, 2026. The total authorized share capital remained at RMB 446,898,420, comprising RMB 110,781,920 in H shares and RMB 336,116,500 in A shares.</p>\n<p>According to the announcement, there were no changes to the number of issued shares for either the H-share or A-share classes during the reporting period. The H-share count stood at 110,781,920, while the A-share count remained 336,116,500. No treasury shares or other share movements were reported.</p>\n<p>In addition, the public float requirement for the listed H shares was met as of the end of January 2026, with no disclosures regarding any non-compliance. The company did not report any details on share options, warrants, convertibles, or other share issuance arrangements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1181959686","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181959686","pubTimestamp":1770110677,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. presented a monthly return of equity movements for the period ended January 31, 2026. The total authorized share capital remained at RMB 446,898,420,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"百奥赛图药业（北京）有限公司(02315)公布2026年1月股本及公众持股量更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. presented a monthly return of equity movements for the period ended January 31, 2026. The total authorized share capital remained at RMB 446,898,420, comprising RMB 110,781,920 in H shares and RMB 336,116,500 in A shares.\nAccording to the announcement, there were no changes to the number of issued shares for either the H-share or A-share classes during the reporting period. The H-share count stood at 110,781,920, while the A-share count remained 336,116,500. No treasury shares or other share movements were reported.\nIn addition, the public float requirement for the listed H shares was met as of the end of January 2026, with no disclosures regarding any non-compliance. The company did not report any details on share options, warrants, convertibles, or other share issuance arrangements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}